Pre-Seed Round
Target $500K
Capital will accelerate core product engineering and launch primary clinical pilots with strategic healthcare partners.
Provide your professional contact details to receive our latest investor materials.
Partner with Healus
Healus is a patient-centric mental health technology firm closing the gap in standard care. We provide clinicians and patients with infrastructure for continuous support between sessions, ensuring no patient manages their recovery alone.
Seed Round
Inquire for Details
Funding will drive hardware manufacturing scale, clinical team expansion, and the growth of our national distribution network.
Briefly describe your fund or investment thesis to initiate a discovery call.
Investor Roadmap
A strategic overview of our funding goals, validated milestones, and growth trajectory.
Current Round
Pre-Seed
Target Funding
$500,000
Use of Funds
Product & Pilots
Timeline
Q3 2026 - Q2 2027
Milestone 1: Foundation & Concept
Completed
What we proved:
• We mapped the clinical failure point by identifying the unmonitored window between appointments where relapse is most likely, validated through 40+ structured interviews.
• Healus confirmed that no existing solutions provide real-time support outside of scheduled care, proving the gap is structural.
• Our team established a clinical rationale for hardware-enabled intervention based on behavioral health literature regarding adherence and crisis patterns.
• We successfully launched the Healus brand and digital presence, confirming immediate market interest via our active waitlist.
Milestone 2: Technology & Ecosystem
Now
What we are doing right now:
• Our team is building the core technology stack and executing development sprints to ensure prototype readiness for upcoming pilots.
• We are meeting with clinical leads to pressure-test the Healus product design against real-world psychiatric workflows.
• We are maintaining active dialogue with three early-stage health-tech funds and have finalized our data room.• Healus is applying to top-tier accelerators for the Q2/Q3 2026 cycles to secure institutional validation.
• We are pursuing non-dilutive capital through NIH SBIR pathways to extend our operational runway.
Milestone 3: Pre-Seed Close & First Pilots
Q3 2026
What will be true by Q3 2026:
• The pre-seed round will close at $500,000, with all capital allocated to product completion and regulatory groundwork.
• Healus will deploy a functional prototype with clinical partners under structured observation and outcome tracking protocols.
• We will generate real-world data on engagement and safety to support our evidence-based seed round narrative.
• Our legal counsel will confirm the FDA device classification strategy for all regulatory audiences.
• We will finalize our primary revenue model, such as SaaS or health system licensing, based on direct pilot results.
Milestone 4: Seed Round & Scaled Operations
Post-Seed
Where the pre-seed data takes us:
• Healus will raise a seed round of $2M to $5M based on clinical outcomes and proven pilot revenue.
• We will scale manufacturing with supply chain partners while implementing rigorous quality and safety protocols.
• Our clinical success team will manage partner onboarding to ensure high efficacy during rapid expansion.
• We will initiate payer partnership conversations using real-world data to secure sustainable reimbursement pathways.
• Healus will prove unit economics at scale before initiating a deliberate nationwide market rollout.
Milestone 5: Category Standard
Vision
The inevitable destination:
• Healus will become the standard infrastructure for mental health care, bridging the gap between every clinical appointment.
• Our solution will be reimbursable through major payer networks via a validated CPT code strategy.
• We will publish peer-reviewed data to cement the credibility of Healus with academic medical centers and regulators.
• The company will expand into global markets where mental health infrastructure gaps are most acute.
• Healus will achieve a category-defining exit through a strategic acquisition or IPO as the leader in continuous mental health care.